Hong Kong Scientists Develop Drug To Starve Cancer Cells
This article was originally published in PharmAsia News
Hong Kong researchers say they have developed a drug capable of preventing cancer cells from growing by starving them of the nutrient arginine. The Hong Kong Polytechnic University scientists said they used the arginase enzyme to degrade arginine, producing urea as an end product. Their tests of the drug in cell cultures shows it can work for breast, cervical, colorectal, gastric, lung, pancreatic and skin cancers. The tests also showed the drug does not affect normal cells nearby. (Click here for more
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.